Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CFR64 T
- Development stage
- Phase 2
- Lead developer
- Gates Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CFR64 T cells are a type of engineered T cell therapy that express a chimeric Fc receptor CD64 (CFR64). This therapy is designed to enhance antitumor activity by providing a controllable and long-lasting immune response. CFR64 T cells exhibit robust cytotoxicity against cancer cells and show better resistance to T cell exhaustion compared to conventional CAR T cells. They are engineered to work with antibodies like trastuzumab, forming a stable immunological synapse and inducing long-term antitumor effects.
02
Targets
IgG Fc (Immunoglobulin G Fc region)
Beyond the preview
Go deeper on CFR64 T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CFR64 T.